Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

February 19, 2025

The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.

February 17, 2025

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

February 14, 2025

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

February 07, 2025

Matthew Cortese, MD, MPH, discusses an evaluation of immunologic changes with the treatment of venetoclax in patients with chronic lymphocytic leukemia.

January 30, 2025

Marco Davila, MD, PhD, discusses emerging strategies to overcome resistance to CD19-directed CAR T-cell therapy in aggressive large B-cell lymphoma.

January 20, 2025

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

January 20, 2025

Marco Davila, MD, PhD, explains the role of intrinsic tumor drivers in CD19 CAR T-cell therapy resistance in aggressive large B-cell lymphoma.

January 20, 2025

Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.

January 03, 2025

Data published in Oncogene suggest that the mitochondrial unfolded protein response could be an Achilles’ heel for neuroendocrine prostate cancer.

December 20, 2024

A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.

December 16, 2024

Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.

December 08, 2024

Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, sits down with Chandler Park, MD, FACP, to discuss the latest in acute myeloid leukemia from the 2024 ASH Annual Meeting.

December 05, 2024

Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas

November 28, 2024

A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.

November 25, 2024

More than a dozen teams to share advances in blood cancer treatment and research innovations at the 2024 ASH Annual Meeting.

November 19, 2024

Nurse-executive and partnership manager honored for dedication to local heroes.

November 06, 2024

Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.

October 30, 2024

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

October 16, 2024

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

October 11, 2024

Francisco Hernandez-Ilizaliturri, MD, discusses factors that inform the selection of CAR T-cell therapies for patients with follicular lymphoma.